Kymera Therapeutics, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 2.93M34.03M72.83M46.83M78.59M3.10M
Gross Profit 2.93M34.03M72.83M46.83M78.59M3.10M
Operating items
Research & Development 37.16M62.10M137.02M164.25M189.08M240.25M
Selling, General & Administrative 7.98M18.23M36.34M43.83M55.04M63.53M
Other Operating Expenses 4.92M
Operating Expenses 45.14M80.34M173.36M208.08M244.12M308.71M
Operating Income -42.20M-46.30M-100.53M-161.26M-165.53M-261.63M
EBIT -42.20M-46.30M-100.53M-161.26M-165.53M-261.63M
Non-operating items
Other Non Operating Income 1.00M0.83M0.49M6.62M18.76M38.03M
Non Operating Income 0.96M0.71M0.31M6.45M18.57M37.78M
Net income details
EBT -42.25M-46.42M-100.70M-161.43M-165.73M-261.88M
Profit After Tax -41.25M-45.59M-100.22M-154.81M-146.96M-223.86M
Income from Continuing Operations -42.25M-46.42M-100.70M-161.43M-165.73M-261.88M
Consolidated Net Income -42.25M-46.42M-100.70M-161.43M-165.73M-261.88M
Income towards Parent Company -42.25M-46.42M-100.70M-161.43M-165.73M-261.88M
Preferred Dividend Payments 9.05M
Net Income towards Common Stockholders -41.25M-54.64M-100.70M-154.81M-146.96M-223.86M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 41.72M44.46M51.39M55.18M61.11M64.94M
Shares Outstanding (Diluted Average) 17.35M47.99M53.93M58.37M75.04M
EBITDA -41.24M-45.73M-100.75M-159.10M-142.56M-224.79M